Yasutomo Nakai

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma.

Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma.

Journal: Scientific reports

Published: April 02, 2026

A Case of Reactive Lymphoid Hyperplasia That Is Difficult to Differentiate From Renal Cancer With Lymph Node Metastasis.

A Case of Reactive Lymphoid Hyperplasia That Is Difficult to Differentiate From Renal Cancer With Lymph Node Metastasis.

Journal: IJU case reports

Published: January 19, 2026

Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.

Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: December 19, 2025

Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.

Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.

Journal: Scientific reports

Published: July 06, 2025

Trends in real-world outcomes of patients with metastatic renal cell cancer in the recent treatment era: a single-institution analysis.

Trends in real-world outcomes of patients with metastatic renal cell cancer in the recent treatment era: a single-institution analysis.

Journal: International journal of clinical oncology

Published: May 01, 2025

Characteristics of patients with metastatic renal cell carcinoma who do not respond to axitinib treatment.

Characteristics of patients with metastatic renal cell carcinoma who do not respond to axitinib treatment.

Journal: International journal of clinical oncology

Published: December 10, 2024

Risk assessment of late biochemical recurrence after radical prostatectomy: Usefulness of ultra-sensitive prostate-specific antigen measurement.

Risk assessment of late biochemical recurrence after radical prostatectomy: Usefulness of ultra-sensitive prostate-specific antigen measurement.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: August 06, 2024

Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan.

Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan.

Journal: International journal of clinical oncology

Published: June 23, 2024

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.

Journal: Clinical and experimental medicine

Published: April 29, 2024

Outcomes in patients with high- and very high-risk localized prostate cancer treated with definitive IMRT and long-term hormone therapy.

Outcomes in patients with high- and very high-risk localized prostate cancer treated with definitive IMRT and long-term hormone therapy.

Journal: Japanese journal of clinical oncology

Published: October 29, 2023

Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy.

Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy.

Journal: International cancer conference journal

Published: June 12, 2023

A Case of Primary Signet Ring Cell Carcinoma of the Urinary Bladder Showing Effectiveness of Chemotherapy with Gemcitabine and Cisplatin

A Case of Primary Signet Ring Cell Carcinoma of the Urinary Bladder Showing Effectiveness of Chemotherapy with Gemcitabine and Cisplatin

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: May 14, 2023

Showing 1-12 of 70

Last Updated: 09/26/2026